Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion

Research output: Contribution to journalJournal articleResearchpeer-review


  • Kathleen M Andersen
  • Ayano Kelly
  • Anne Lyddiatt
  • Clifton O Bingham
  • Vivian P Bykerk
  • Adena Batterman
  • Joan Westreich
  • Michelle K Jones
  • Marita Cross
  • Peter M Brooks
  • Lyn March
  • Beverley Shea
  • Peter Tugwell
  • Lee S Simon
  • Robin Christensen
  • Susan J Bartlett
View graph of relations

OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease.

METHODS: International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees.

RESULTS: Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence.

CONCLUSION: Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.

Original languageEnglish
JournalJournal of Rheumatology
Issue number9
Pages (from-to)1168-1172
Number of pages5
Publication statusPublished - Sep 2019

    Research areas

  • Clinical trials, Disease-modifying antirheumatic drugs, Drug toxicity, OMERACT, Patient satisfaction, Risk

ID: 58098031